Search Within

Martin Stuart Tallman

Formats
  1. Journal Article (323)
  2. Meeting Abstract (280)
  3. Review (19)
  4. Editorial (10)
  5. Book Section (8)
  6. Research Letter (8)
  7. Guidelines (6)
  8. Correspondence (1)
Groups
  1. Adult Leukemia (655)
  2. Center for Hematologic Malignancies (655)
  3. Department of Medicine (655)
  4. Hematologic Malignancies, Division of (655)
  5. GSK Faculty (164)
  6. Executive Committee, Center for Hematologic Malignancies (156)

More Groups

People
  1. Ross Levine (131)
  2. Eytan Stein (118)
  3. Jae Park (81)
  4. Omar Abdel-Wahab (68)
  5. Sean Devlin (65)
  6. Dan Douer (50)

More People

Years
  1. 2025 (6)
  2. 2024 (10)
  3. 2023 (10)
  4. 2022 (26)
  5. 2021 (45)
  6. 2020 (51)

More Years

Publications
  1. Blood (274)
  2. Journal of Clinical Oncology (41)
  3. Blood Advances (27)
  4. Leukemia Research (27)
  5. Leukemia and Lymphoma (26)
  6. Haematologica (25)

More Publications

Publishers
  1. American Society of Hematology (301)
  2. Elsevier Inc. (44)
  3. American Society of Clinical Oncology (41)
  4. Nature Publishing Group (38)
  5. Taylor & Francis Group (28)
  6. Elsevier Ltd (27)

More Publishers

Results (655)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • RNA binding protein SYNCRIP regulates the leukemia stem cell program
    Meeting Abstract

    Vu, L. P.; Prieto, C.; Amin, E.; Minuesa, G.; Chhangawala, S.; Vidal, M. J.; Krivtsov, A. V.; Chou, T.; Barlowe, T.; Taggart, J.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Enasidenib (AG-221), a potent oral inhibitor of mutant isocitrate dehydrogenase 2 (IDH2) enzyme, induces hematologic responses in patients with myelodysplastic syndromes (MDS)
    Meeting Abstract

    Stein, E. M.; Fathi, A. T.; DiNardo, C. D.; Pollyea, D. A.; Swords, R. T.; Roboz, G. J.; Collins, R.; Sekeres, M. A.; Stone, R. M.; Attar, E. C.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • ATRA, arsenic trioxide (ATO), and gemtuzumab ozogamicin (GO) is safe and highly effective in patients with previously untreated high-risk acute promyelocytic leukemia (APL): Final results of the SWOG/Alliance/ECOG S0535 trial
    Meeting Abstract

    Lancet, J. E.; Moseley, A.; Komrokji, R. S.; Coutre, S. E.; DeAngelo, D. J.; Tallman, M. S.; Litzow, M.; Othus, M.; Appelbaum, F. R.
    Blood (2016)

    Fulltext@MSK | Save
  • Combined treatment with lenalidomide (LEN) and epoetin alfa (EA) is superior to lenalidomide alone in patients with erythropoietin (Epo)-refractory, lower risk (LR) non-deletion 5q [Del(5q)] myelodysplastic syndrome (MDS): Results of the E2905 Intergroup Study - an ECOG-ACRIN Cancer Research Group study, grant CA180820, and the National Cancer Institute of the National Institutes of Health
    Meeting Abstract

    List, A. F.; Sun, Z.; Verma, A.; Bennett, J. M.; McGraw, K. L.; Nardelli, L. A.; Maciejewski, J. P.; Altman, J. K.; Cheema, P.; Claxton, D. F.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Pembrolizumab, a PD-1 inhibitor, in patients with myelodysplastic syndrome (MDS) after failure of hypomethylating agent treatment
    Meeting Abstract

    Garcia-Manero, G.; Tallman, M. S.; Martinelli, G.; Ribrag, V.; Yang, H.; Balakumaran, A.; Chlosta, S.; Zhang, Y.; Smith, B. D.
    Blood (2016)

    Fulltext@MSK | Save
  • Multicolor flow cytometry and multi-gene next generation sequencing are complimentary and highly predictive for relapse in acute myeloid leukemia following allogeneic hematopoietic stem cell transplant
    Meeting Abstract

    Getta, B. M.; Devlin, S.; Maloy, M. A.; Mohanty, A.; Arcila, M.; Tallman, M. S.; Levine, R. L.; Giralt, S. A.; Roshal, M.
    Blood (2016)

    Fulltext@MSK | Save
  • Cooperative gene repression by DNA methylation and LSD1-mediated enhancer inactivation in acute myeloid leukemia
    Meeting Abstract

    Duy, C.; Teater, M.; Garrett-Bakelman, F. E.; Lee, T. C.; Meydan, C.; Glass, J. L.; Li, M.; Mohammad, H.; Smitheman, K.; Shih, A. H.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Importance of achieving complete remission (CR) after intensive therapy for acute myeloid leukemia (AML) in older adults age >= 60 years: Analysis of risk factors for early mortality and re-induction, and impact of quality of response on overall survival (OS) in the ECOG-ACRIN E2906 randomized trial
    Meeting Abstract

    Foran, J. M.; Sun, Z.; Claxton, D. F.; Lazarus, H. M.; Thomas, M. L.; Melnick, A.; Levine, R. L.; Paietta, E.; Arber, D. A.; Zhang, Y.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Mutational analysis of clonal hematopoiesis in solid tumor patients illustrates the critical role of systemic anti-cancer therapies in the evolution of somatic leukemia disease alleles
    Meeting Abstract

    Coombs, C. C.; Zehir, A.; Devlin, S.; Kishtagari, A.; Hyman, D. M.; Solit, D.; Robson, M.; Baselga, J.; Arcila, M.; Tallman, M. S.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Determination of IDH1 mutational burden and clearance via next-generation sequencing in patients with IDH1 mutation-positive hematologic malignancies receiving AG-120, a first-in-class inhibitor of mutant IDH1
    Meeting Abstract

    DiNardo, C. D.; de Botton, S.; Stein, E. M.; Roboz, G. J.; Swords, R. T.; Pollyea, D. A.; Fathi, A. T.; Collins, R.; Altman, J. K.; Flinn, I. W.; more...
    Blood (2016)

    Fulltext@MSK | Save